Personal tools

CL:0000988

From FANTOM5_SSTAR

Jump to: navigation, search
Name:hematopoietic cell
Namespace:FANTOM
Definition:"A cell of a hematopoietic lineage." [GO_REF:0000031, GOC:add]
Xrefs:
links:

BTO:0000574
FMA:70366

FMA:83598
Synonyms: "haematopoietic cell" EXACT []
"haemopoietic cell" EXACT []
"hemopoietic cell" EXACT []


Ontology association
Each term has an is_a parent in the Cell ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to Cell ontologies.

link to ontology dataset
data


Parents

is_a:CL:0000548(animal cell),CL:0002371(somatic cell)



Children


is a:CL:0000080 (circulating cell),CL:0000081 (blood cell),CL:0000738 (leukocyte),CL:0000763 (myeloid cell),CL:0008001 (hematopoietic precursor cell),CL:1001610 (bone marrow hematopoietic cell)
derives from:FF:0101035 (hematopoietic cell line sample)

Ontology Tree: Loaded from BioPortal


FF samples
It includes FANTOM5 samples that overlay the Cell ontology.


Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
  • 10421-106C7 (adult T-cell leukemia cell line:ATN-1)
  • 10422-106C8 (Burkitt's lymphoma cell line:DAUDI)
  • 10427-106D4 (b cell line:RPMI1788)
  • 10429-106D6 (acute lymphoblastic leukemia (T-ALL) cell line:HPB-ALL)
  • 10435-106E3 (Hodgkin's lymphoma cell line:HD-Mar2)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
  • 10421-106C7 (adult T-cell leukemia cell line:ATN-1)
  • 10422-106C8 (Burkitt's lymphoma cell line:DAUDI)
  • 10427-106D4 (b cell line:RPMI1788)
  • 10429-106D6 (acute lymphoblastic leukemia (T-ALL) cell line:HPB-ALL)
  • 10435-106E3 (Hodgkin's lymphoma cell line:HD-Mar2)

... further results


Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with CL:0000988 (hematopoietic cell), sorted by p-values
Analyst: Hideya Kawaji

link to source dataset
human : data
mouse : data


P-valueFFCPShort description
8.14e-116FFCP PHASE1:Hg19::chr1:206730535..206730549,+#_c24c61fec9696544da3c550217168898p4@RASSF5
8.14e-116FFCP PHASE2:Hg19::chr1:206730535..206730549,+#_c24c61fec9696544da3c550217168898p4@RASSF5
1.31e-113FFCP PHASE1:Hg19::chr2:68592394..68592405,+#_957aae33a365bb57c85c04a960c12127p2@PLEK
1.31e-113FFCP PHASE2:Hg19::chr2:68592394..68592405,+#_957aae33a365bb57c85c04a960c12127p2@PLEK
3.18e-110FFCP PHASE1:Hg19::chr7:50344251..50344288,+#_2b84a62f16431f924f9e2d9c9047d242p3@IKZF1
3.18e-110FFCP PHASE2:Hg19::chr7:50344251..50344288,+#_2b84a62f16431f924f9e2d9c9047d242p3@IKZF1
5.7e-109FFCP PHASE2:Hg19::chr5:169724839..169724855,-#_d750ad97ea37a6cbb9d4c799512a0f38p3@LCP2
5.7e-109FFCP PHASE1:Hg19::chr5:169724839..169724855,-#_d750ad97ea37a6cbb9d4c799512a0f38p3@LCP2
1.37e-104FFCP PHASE1:Hg19::chr2:143886927..143886938,+#_71a944731b80e78e46a3b094ae596cefp3@ARHGAP15
1.37e-104FFCP PHASE2:Hg19::chr2:143886927..143886938,+#_71a944731b80e78e46a3b094ae596cefp3@ARHGAP15
6.01e-104FFCP PHASE2:Hg19::chr2:144021511..144021516,+#_2782b2983ae33ff167a1ca33170203a7p@chr2:144021511..144021516, +
6.01e-104FFCP PHASE1:Hg19::chr2:144021511..144021516,+#_2782b2983ae33ff167a1ca33170203a7p@chr2:144021511..144021516, +
1.09e-103FFCP PHASE1:Hg19::chr2:143886909..143886922,+#_316ac51118a49930b49f7d7c5240c0fep2@ARHGAP15
1.09e-103FFCP PHASE2:Hg19::chr2:143886909..143886922,+#_316ac51118a49930b49f7d7c5240c0fep2@ARHGAP15
2.28e-103FFCP PHASE2:Hg19::chr1:202129704..202129762,-#_bcc4f6fc8980c3db98e6a711f8c875d1p1@PTPN7
2.28e-103FFCP PHASE1:Hg19::chr1:202129704..202129762,-#_bcc4f6fc8980c3db98e6a711f8c875d1p1@PTPN7
1.1e-102FFCP PHASE1:Hg19::chr1:206730484..206730499,+#_1181fbaf2b42ac7b63a2b082208444c5p2@RASSF5
1.1e-102FFCP PHASE2:Hg19::chr1:206730484..206730499,+#_1181fbaf2b42ac7b63a2b082208444c5p2@RASSF5
1.29e-102FFCP PHASE2:Hg19::chr2:143886890..143886904,+#_ec49bdfe6fd61778c38f5a37015f0b5ep4@ARHGAP15
1.29e-102FFCP PHASE1:Hg19::chr2:143886890..143886904,+#_ec49bdfe6fd61778c38f5a37015f0b5ep4@ARHGAP15
4.62e-102FFCP PHASE2:Hg19::chr10:11207485..11207496,+#_68c1ddc08c6ea22911c15d090d72882bp9@CELF2
4.62e-102FFCP PHASE1:Hg19::chr10:11207485..11207496,+#_68c1ddc08c6ea22911c15d090d72882bp9@CELF2
2.76e-101FFCP PHASE2:Hg19::chr7:45018571..45018589,-#_7a23b4422ab0720d03b44a62cd8c9429p3@MYO1G
2.76e-101FFCP PHASE1:Hg19::chr7:45018571..45018589,-#_7a23b4422ab0720d03b44a62cd8c9429p3@MYO1G
5.72e-101FFCP PHASE1:Hg19::chr19:2085323..2085357,-#_188acae3f131f3b1ccd0dc542fc1f97bp2@MOB3A
5.72e-101FFCP PHASE2:Hg19::chr19:2085323..2085357,-#_188acae3f131f3b1ccd0dc542fc1f97bp2@MOB3A
1.66e-100FFCP PHASE1:Hg19::chr1:26872324..26872362,+#_397e746d078dd8b105cb3c152991d114p1@RPS6KA1
1.66e-100FFCP PHASE2:Hg19::chr1:26872324..26872362,+#_397e746d078dd8b105cb3c152991d114p1@RPS6KA1
2.15e-100FFCP PHASE2:Hg19::chr11:73694239..73694253,-#_5a4156b8acbac7b990558cd9d3a6f87cp2@UCP2
2.15e-100FFCP PHASE1:Hg19::chr11:73694239..73694253,-#_5a4156b8acbac7b990558cd9d3a6f87cp2@UCP2
2.24e-99FFCP PHASE1:Hg19::chr12:54891496..54891526,+#_0b0c1af94b48e82d7fb268495d658ee4p2@NCKAP1L
2.24e-99FFCP PHASE2:Hg19::chr12:54891496..54891526,+#_0b0c1af94b48e82d7fb268495d658ee4p2@NCKAP1L
4.55e-99FFCP PHASE2:Hg19::chr1:161039647..161039744,-#_c9d03b292a26eb5f8c7f867d9ae2c82ap1@ARHGAP30
4.55e-99FFCP PHASE1:Hg19::chr1:161039647..161039744,-#_c9d03b292a26eb5f8c7f867d9ae2c82ap1@ARHGAP30
1.29e-98FFCP PHASE1:Hg19::chr20:34078776..34078819,-#_00c11bf05ed0f767c5f61af450366e7cp1@ENST00000453914
1.29e-98FFCP PHASE2:Hg19::chr20:34078776..34078819,-#_00c11bf05ed0f767c5f61af450366e7cp1@ENST00000453914
1.68e-98FFCP PHASE2:Hg19::chr1:206730595..206730630,+#_5ea213957be92e85c5ac902ce21119a2p3@RASSF5
1.68e-98FFCP PHASE1:Hg19::chr1:206730595..206730630,+#_5ea213957be92e85c5ac902ce21119a2p3@RASSF5
1.77e-98FFCP PHASE1:Hg19::chr19:17862274..17862335,+#_9e9659246d4e4ab3e5c27f0b600b5f9fp2@FCHO1
1.77e-98FFCP PHASE2:Hg19::chr19:17862274..17862335,+#_9e9659246d4e4ab3e5c27f0b600b5f9fp2@FCHO1
2.22e-98FFCP PHASE2:Hg19::chr17:56415424..56415454,-#_9871787b14814ab24423ec0d48714fe5p@chr17:56415424..56415454, -
2.22e-98FFCP PHASE1:Hg19::chr17:56415424..56415454,-#_9871787b14814ab24423ec0d48714fe5p@chr17:56415424..56415454, -
2.24e-98FFCP PHASE2:Hg19::chr5:169064317..169064332,+#_ea9d148d0c919a6a91f1742825c081a9p2@DOCK2
2.24e-98FFCP PHASE1:Hg19::chr5:169064317..169064332,+#_ea9d148d0c919a6a91f1742825c081a9p2@DOCK2
3.47e-98FFCP PHASE2:Hg19::chr7:45018686..45018710,-#_f785be7ecba56825664d8323231474b9p2@MYO1G
3.47e-98FFCP PHASE1:Hg19::chr7:45018686..45018710,-#_f785be7ecba56825664d8323231474b9p2@MYO1G
5.94e-98FFCP PHASE1:Hg19::chrX:128913876..128913904,+#_cc66b1465b4298adb69cb3674832fd70p2@SASH3
5.94e-98FFCP PHASE2:Hg19::chrX:128913876..128913904,+#_cc66b1465b4298adb69cb3674832fd70p2@SASH3
8.42e-98FFCP PHASE2:Hg19::chr17:56414688..56414711,+#_756853963cc471b899bcd38b001a68d8p1@uc002iwa.2, p1@uc002iwb.2, p1@uc002iwc.2
8.42e-98FFCP PHASE1:Hg19::chr17:56414688..56414711,+#_756853963cc471b899bcd38b001a68d8p1@uc002iwa.2, p1@uc002iwb.2, p1@uc002iwc.2
9.25e-98FFCP PHASE1:Hg19::chr19:14551066..14551097,+#_3229509b6c3c787b96e9b067ab18579dp2@PKN1
9.25e-98FFCP PHASE2:Hg19::chr19:14551066..14551097,+#_3229509b6c3c787b96e9b067ab18579dp2@PKN1
9.43e-98FFCP PHASE1:Hg19::chr11:64107705..64107718,+#_16db488c60291d4471b8b3d4df83a6a8p2@CCDC88B
9.43e-98FFCP PHASE2:Hg19::chr11:64107705..64107718,+#_16db488c60291d4471b8b3d4df83a6a8p2@CCDC88B
1.21e-97FFCP PHASE2:Hg19::chr1:151129103..151129130,+#_d018a92aaaaa7f53682973b91a818940p2@TNFAIP8L2
1.21e-97FFCP PHASE1:Hg19::chr1:151129103..151129130,+#_d018a92aaaaa7f53682973b91a818940p2@TNFAIP8L2
1.4e-97FFCP PHASE1:Hg19::chr2:24149046..24149063,+#_49f81dac4b507cc1191712c633734c8fp@chr2:24149046..24149063, +
1.4e-97FFCP PHASE2:Hg19::chr2:24149046..24149063,+#_49f81dac4b507cc1191712c633734c8fp@chr2:24149046..24149063, +
2.1e-97FFCP PHASE1:Hg19::chr7:50344289..50344323,+#_d2138896efb7081b13485778e50a029ap1@IKZF1
2.1e-97FFCP PHASE2:Hg19::chr7:50344289..50344323,+#_d2138896efb7081b13485778e50a029ap1@IKZF1
2.83e-97FFCP PHASE2:Hg19::chr21:15918672..15918683,-#_b3b1adc3874771a59e784c8c5e0d2c97p2@SAMSN1
2.83e-97FFCP PHASE1:Hg19::chr21:15918672..15918683,-#_b3b1adc3874771a59e784c8c5e0d2c97p2@SAMSN1
4.25e-97FFCP PHASE2:Hg19::chr7:45018602..45018625,-#_b32e08b676d46fdb9e314e56f94ffdedp1@MYO1G
4.25e-97FFCP PHASE1:Hg19::chr7:45018602..45018625,-#_b32e08b676d46fdb9e314e56f94ffdedp1@MYO1G
9.14e-97FFCP PHASE1:Hg19::chr11:67034140..67034180,+#_0b455fafe50c5ffc6601ffa0731328eep2@ADRBK1
9.14e-97FFCP PHASE2:Hg19::chr11:67034140..67034180,+#_0b455fafe50c5ffc6601ffa0731328eep2@ADRBK1
1.5e-96FFCP PHASE2:Hg19::chr22:18260077..18260127,+#_0ed38cc983a7b5f0c7ec7091aeafbb61p1@LINC00528
1.5e-96FFCP PHASE1:Hg19::chr22:18260077..18260127,+#_0ed38cc983a7b5f0c7ec7091aeafbb61p1@LINC00528
8.32e-96FFCP PHASE2:Hg19::chr1:111415786..111415804,+#_c30c4c19265d3cef6b4bdb46b8e8d92cp2@CD53
8.32e-96FFCP PHASE1:Hg19::chr1:111415786..111415804,+#_c30c4c19265d3cef6b4bdb46b8e8d92cp2@CD53
9.51e-96FFCP PHASE1:Hg19::chr19:36393354..36393363,+#_0988aa52b2ad573f026dadd751ba01d4p4@HCST
9.51e-96FFCP PHASE2:Hg19::chr19:36393354..36393363,+#_0988aa52b2ad573f026dadd751ba01d4p4@HCST
1.58e-95FFCP PHASE1:Hg19::chr1:209929388..209929412,+#_fe180a7483ff8602e5a2f1cf1a6cf4d5p3@TRAF3IP3
1.58e-95FFCP PHASE2:Hg19::chr1:209929388..209929412,+#_fe180a7483ff8602e5a2f1cf1a6cf4d5p3@TRAF3IP3
2.12e-95FFCP PHASE2:Hg19::chr9:273038..273076,+#_e6b585184a350e5243f86d05c47ff3ebp2@DOCK8
2.12e-95FFCP PHASE1:Hg19::chr9:273038..273076,+#_e6b585184a350e5243f86d05c47ff3ebp2@DOCK8
2.94e-95FFCP PHASE2:Hg19::chr19:10450328..10450351,-#_7cea8901e397446a8ae54feb77fb297cp2@ICAM3
2.94e-95FFCP PHASE1:Hg19::chr19:10450328..10450351,-#_7cea8901e397446a8ae54feb77fb297cp2@ICAM3
5.08e-95FFCP PHASE2:Hg19::chr3:151962118..151962192,+#_b785560778185bb2a2b4fd6e072eeb77p@chr3:151962118..151962192, +
5.08e-95FFCP PHASE1:Hg19::chr3:151962118..151962192,+#_b785560778185bb2a2b4fd6e072eeb77p@chr3:151962118..151962192, +
2.85e-94FFCP PHASE2:Hg19::chr16:50715172..50715194,-#_25866d0b6527903e83e112612a67f40dp2@SNX20
2.85e-94FFCP PHASE1:Hg19::chr16:50715172..50715194,-#_25866d0b6527903e83e112612a67f40dp2@SNX20
3.23e-94FFCP PHASE1:Hg19::chr19:1067256..1067270,+#_82b1b4d6d321877a13f30293ace46a19p4@HMHA1
3.23e-94FFCP PHASE2:Hg19::chr19:1067256..1067270,+#_82b1b4d6d321877a13f30293ace46a19p4@HMHA1
3.34e-94FFCP PHASE2:Hg19::chr3:196366555..196366572,+#_a7f6a4d749facacb52b73c1f11aaf782p2@LRRC33
3.34e-94FFCP PHASE1:Hg19::chr3:196366555..196366572,+#_a7f6a4d749facacb52b73c1f11aaf782p2@LRRC33
4.11e-94FFCP PHASE2:Hg19::chr19:49842010..49842054,+#_10413dccfcd153e4d4edcc0e1c0a2cdfp@chr19:49842010..49842054, +
4.11e-94FFCP PHASE1:Hg19::chr19:49842010..49842054,+#_10413dccfcd153e4d4edcc0e1c0a2cdfp@chr19:49842010..49842054, +
4.54e-94FFCP PHASE1:Hg19::chr1:31230687..31230701,-#_f9e69ef56acb49cc353b786f4bb0d871p3@LAPTM5
4.54e-94FFCP PHASE2:Hg19::chr1:31230687..31230701,-#_f9e69ef56acb49cc353b786f4bb0d871p3@LAPTM5
7.55e-94FFCP PHASE2:Hg19::chrX:30595907..30595941,-#_b463dbcfce7096664f0a785755525bafp2@CXorf21
7.55e-94FFCP PHASE1:Hg19::chrX:30595907..30595941,-#_b463dbcfce7096664f0a785755525bafp2@CXorf21
1.61e-93FFCP PHASE2:Hg19::chr12:57871853..57871879,-#_90060865916de2bcdf850b6d0dbb53e2p6@ARHGAP9
1.61e-93FFCP PHASE1:Hg19::chr12:57871853..57871879,-#_90060865916de2bcdf850b6d0dbb53e2p6@ARHGAP9
1.77e-93FFCP PHASE1:Hg19::chr6:32159579..32159592,-#_4169615468124ab9aa6ee0f1987abd00p@chr6:32159579..32159592, -
1.77e-93FFCP PHASE2:Hg19::chr6:32159579..32159592,-#_4169615468124ab9aa6ee0f1987abd00p@chr6:32159579..32159592, -
2.43e-93FFCP PHASE2:Hg19::chr1:39680895..39680915,+#_827347c85372240e5980de285ea74b6cp7@MACF1
2.43e-93FFCP PHASE1:Hg19::chr1:39680895..39680915,+#_827347c85372240e5980de285ea74b6cp7@MACF1
3.33e-93FFCP PHASE2:Hg19::chr17:56409871..56409890,-#_3c052f27475bc42f244bf2df3c5b72bbp1@AX721088
3.33e-93FFCP PHASE1:Hg19::chr17:56409871..56409890,-#_3c052f27475bc42f244bf2df3c5b72bbp1@AX721088